MannKind Corporation (NASDAQ:MNKD) Q3 2022 Results Conference Call November 8, 2022 9:00 AM ET
Company Participants
Michael Castagna - Chief Executive Officer
Steven Binder - Chief Financial Officer
Conference Call Participants
Brandon Folkes - Cantor Fitzgerald
Gregory Renza - RBC Capital Markets
Robert Hazlett - BTIG
Operator
Good morning, and welcome to the MannKind Corporation Third Quarter 2022 Earnings Call.
As a reminder, this call is being recorded on November 8, 2022, and will be available for playback on the MannKind Corporation website shortly after the conclusion of this call until November 22, 2022. This call will contain forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from these stated expectations. For further information on the company's risk factors, please see their 10-Q report filed with the Securities and Exchange Commission this morning, the earnings release and the slides prepared for this presentation.
Joining us today from MannKind are Chief Executive Officer, Michael Castagna; and Chief Financial Officer, Steven Binder. I would now like to turn the call over to Mr. Castagna. Please go ahead.
Michael Castagna
Good morning. This is Mike Castagna and I hope you can hear me okay? Okay. Sorry, if you not hearing us. I just want to make sure everybody could hear me before I get started.
Good morning, and thank you for joining us for our earnings call today. Today marks the beginning of the new MannKind. You can start to see our execution from a single product to a sustainable growth company. We've never been more excited about our future than now. When you look down, you see four sources of revenue growth and 74% growth quarter-over-quarter. Order of the lung business is really starting to shape up as you look at the collaboration and service revenue with Tyvaso, as I'll talk about clofazimine moving forward.
The Endocrine business also did well at double-digit growth, 28% quarter-over-quarter with Afrezza and V-Go revenues.
When you look at the orphan lung, we're well positioned with Tyvaso DPI growing significantly as we go forward and clofazimine starting to help patients hopefully in 2023. Our EBU has grown year-over-year, but in Q3, we made some changes in integrated V-Go and as you'll see in a minute, that we started to make -- as those changes took place we started to grow our market share month-over-month and quarter-over-quarter.